Biocon Stays The Course For Neulasta, Herceptin Biosimilars
Biocon reported robust first-quarter numbers and remains upbeat on the prospects of taking its biosimilars including pegfilgrastim and trastuzumab to Europe and the US notwithstanding regulatory setbacks faced by some seasoned competitors recently.
You may also be interested in...
ASCO Round-Up: Array, Kite, Exelixis, Pfizer/Merck KGAA, Mylan, Novartis
The annual American Society of Clinical Oncology (ASCO) conference has been ongoing the last several days in Chicago, giving companies the chance to showcase their work in a range of cancers. Here's a look at some of the highlights.
Biocon/Fujifilm Enter Lantus Biosimilar Fray In Japan
Biocon and Fujifilm Pharma have received approval for their biosimilar insulin glargine from Japan's Ministry of Health, Labour and Welfare, marking what the Indian firm termed a "huge credibility milestone" and adding further pressure on innovator Sanofi's Lantus.
Backed By Big Names, Etherna Hopes To Disrupt mRNA Space
Belgian mRNA technologies firm Etherna, which is backed by high profile investors including former Bayer CEO Marijn Dekkers and Moderna co-founder Kenneth Chien, has reoriented its business model. Interim CEO Bernard Sagaert tells In Vivo how the firm hopes to deliver superior products for partners in the rapidly expanding RNA space.